{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"77.7","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with response (complete response \\[CR\\] or partial response \\[PR\\]) according to the revised response criteria for malignant lymphoma per Cheson et al. 2007. CR was demonstrated by disappearance of all evidence of disease in the bone marrow, spleen, liver, and for nodal masses. PR was \\>50% decrease in the sum of product diameters for ≤6 target dominant masses for lymph nodes, spleen nodules, and liver nodules and no size increase in the lymph nodes, spleen, or liver. PD-L1 was assessed by immunohistochemistry (IHC). The percentage of participants with CR and PR as assessed by the investigator is presented for participants with an indeterminate (missing) PD-L1 status.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants from the pooled Cohort 5 received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg or 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.","id":"OG000","title":"Pooled Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"All participants pooled from Cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide), who had an indeterminate PD-L1 status, with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation. The analysis was pre-specified to be a pooled analysis of all participants grouped by disease cohort (DLBCL) and treatment combination (irrespective of dose); therefore data by individual dose were not analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Objective Response Rate (ORR) in Programmed Cell Death Ligand 1 (PD-L1) Indeterminate Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide): Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}